At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Dasatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging
In Brief
A Phase 2 clinical trial evaluating Dasatinib and Quercetin for Aging. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow regulation, mobility, and cognition in older adults, and thus may prevent progression to Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAging
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartMay 2022
First PostedJun 2022
Primary CompletionJan 2024
TodayJul 2026
First PostedJun 21, 2022
Enrollment StartMay 20, 2022
Primary CompletionJan 24, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.0 years ago
Interventions
Dasatinibdrug
Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks
Quercetindrug
Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks